InVivo Therapeutics (NSDQ:NVIV) said today it enrolled the 16th patient in the Inspire study of its neuro-spinal scaffold.
The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
The patient was enrolled at Pittsburgh, Penn.’s Allegheny General Hospital after Drs. Dan Altman, Nestor Tomycz and Terence Julien performed surgery and implantation 21 hours after the patient was injured.
“We are all hoping for the best possible outcome for this and all patients enrolled in the study. This will certainly be a landmark study and once again demonstrates the AHN neurosurgery department’s commitment to world class research endeavors brought to the Pittsburgh region,” principal investigator Dr. Julien said in a prepared statement.
“The patient is stable and the implantation procedure was a success. We now have 16 patients in follow up, and with the reported increase in spinal cord injury incidence during the summer months, we remain on track to complete enrollment into Inspire during the third quarter of this year,” chair & CEO Mark Perrin said in a press release.
In May, InVivo said it would integrate data from the Christopher & Dana Reeve Foundation’s North American Clinical Trials Network Registry in the Contempo registry study which is complementing its ongoing Inspire study.
The company said that the Contempo study looks to provide comprehensive natural history benchmarks for the Inspire study of its neuro-spinal scaffold.
